Company Overview

Fresenius Medical Care AG & Co. KGaA is the world's leading provider of products and services for individuals with renal diseases. The company provides dialysis and related services for individuals with kidney diseases in Germany, the United States, and internationally. It was incorporated in 1996 and is headquartered in Bad Homburg, Germany. Fresenius Medical Care serves approximately 4.1 million patients worldwide who regularly undergo dialysis treatment. As of March 31, 2025, the company treated 299,358 patients across 3,674 dialysis clinics globally and employed 112,035 individuals.

Financial Performance and Market Position

Fresenius Medical Care is a global leader in dialysis care, operating in a critical segment of the healthcare industry. The company's market position is reinforced by its extensive network of clinics and its comprehensive product portfolio.

Full Year 2024 Performance:

Fresenius Medical Care delivered strong results in 2024, achieving 18% operating income growth and reaching the upper end of its outlook. Reported operating income grew by 2%, reported net income by 8%, and the net financial leverage ratio was reduced from 3.2x to 2.9x. A dividend increase of 21% is planned. The FME25 transformation program accelerated its momentum, delivering EUR 221 million in sustainable savings for the full year, exceeding the upgraded target of EUR 200 million. Accumulated savings from the program reached EUR 567 million.

Q3 2024 Performance:

The company reported adjusted earnings per share (EPS) of 45 cents, surpassing estimates and showing a 45.2% year-over-year improvement.

- Revenues: $5.23 billion (EUR 4,760 million), down 3.6% year over year (-2.4% at constant currency), but up 1.9% organically.

- Basic EPS: Increased by 153% to EUR 0.73 (+155% at constant currency). EPS on an outlook base increased by 44% to EUR 0.82.

- Operating Cash Flow: Improved by 30% to EUR 985 million (Q3 2023: EUR 760 million), resulting in a margin of 20.7% (Q3 2023: 15.4%).

Q1 2025 Performance:

Group revenue increased by 3% (+1% at constant currency, +5% organic) to EUR 4,881 million. Operating income significantly increased by 35% (+32% at constant currency) to EUR 331 million, resulting in a margin of 6.8% (Q1 2024: 5.2%).

Key Financial Metrics

- Full Year 2024 Operating Income Growth: 18%

- Full Year 2024 Reported Net Income Growth: 8%

- Q3 2024 Adjusted EPS: 45 cents

- Q3 2024 Revenues: EUR 4,760 million

- Q1 2025 Revenues: EUR 4,881 million

- Q1 2025 Operating Income: EUR 331 million

- FME25 Program Savings (FY2024): EUR 221 million

- Net Financial Leverage Ratio (End 2024): 2.9x

Business Operations and Production Capacity

Fresenius Medical Care AG operates as a dual business: a provider of clinical care services and a manufacturer of dialysis-related products.

- Clinical Care Services (78% of Net Sales): Operated 3,675 institutions as of the end of 2024, serving 299,358 patients across 3,674 clinics.

- Manufacturing of Dialyzers and Products (22% of Net Sales): Includes hemodialysis and pediatric dialysis machines.

Product Portfolio and Market Strategy

The company develops, manufactures, and distributes a wide range of healthcare products essential for kidney disease management.

- Products: Polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions, granulates, bloodlines, renal pharmaceuticals, water treatment systems, and acute cardiopulmonary/apheresis products.

- Pharmaceuticals: Develops, acquires, and in-licenses renal pharmaceuticals, offering medications and supplies to patients at home or in clinics.

- Other Services: Provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, physician nephrology, ambulant treatment, and other related services.

Future Growth Plans and Strategic Initiatives

Fresenius Medical Care is focused on operational excellence and strategic growth through its transformation program and portfolio optimization.

FME25 Transformation Program

The FME25 transformation program is a key initiative driving efficiency and savings. The program's momentum has enabled the company to raise its target for sustainable annual savings from EUR 650 million to EUR 750 million by the end of the current year, an increase of EUR 100 million. Accumulated savings have reached EUR 567 million.

Portfolio Optimization

During 2024, Fresenius Medical Care executed significant divestments as part of its portfolio optimization strategy. This included exits from all Latin American countries, Sub-Saharan Africa, and Türkiye, as well as divestments of Cura Day Hospitals Group in Australia and select assets of Spectra Laboratories. These divested assets comprised 230 facilities, 8,200 employees, and approximately 33,800 dialysis patients.

Geographic Distribution

Net sales are predominantly generated in key markets:

- United States: 70.7%

- Other Regions: 26.8%

- Germany: 2.5%

Stock Exchange Listings

Fresenius Medical Care's ordinary shares have been traded on both the Frankfurt Stock Exchange (FWB) and the New York Stock Exchange (NYSE) in the form of American Depositary Shares (ADS) since 1996. The company's shares are listed in the leading German index DAX and are included in other major international indices such as the Dow Jones, MSCI, and FTSE. Fresenius Medical Care returned to the top tier of the German Stock Index, the DAX, on December 27, 2024.

Shareholder Structure

As of December 31, 2024, the institutional free float was primarily held by:

- United States and Canada: 72.2%

- United Kingdom: 8.8%

- Germany: 5.8%

- France: 3.8%

2025 Outlook

Fresenius Medical Care confirms its outlook for fiscal 2025:

- Revenue Growth: Expected to be positive to a low-single digit percent rate compared to the prior year.

- Operating Income Growth: Expected to grow by a high-teens to high-twenties percent rate compared to the prior year (excluding special items).

- The company aims to significantly grow earnings, raising the implied operating income margin to around 11% to 12% in 2025.

The company continues its strategic focus on operational excellence through the FME25 transformation program while maintaining its position as the global leader in dialysis care and related medical products, serving patients across multiple continents with a comprehensive portfolio of renal care solutions.